A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3cpath%20style='&st5;'%20d='M15.7,14.7c0.1,0.1,0.2,0.1,0.3,0.1c0,0,0,0,0.1,0c0.1,0,0.2-0.1,0.3-0.2l1.9-5.7c0.1-0.2,0-0.4-0.2-0.4%20c-1-0.4-2.2-0.4-3.3-0.2c-1.1,0.2-2.1,0.7-2.9,1.5c-0.1,0.1-0.1,0.3,0,0.5L15.7,14.7z'/%3e%3cpath%20style='&st5;'%20d='M22.5,20.3l-6.5-4.1l-5.1-5.6c-0.1-0.1-0.3-0.1-0.5,0c-2.1,1.8-2.9,4.5-2.3,7.2c0.8,3.7,4.3,6.4,8.1,6.4%20c0,0,0,0,0,0c0.4,0,0.9,0,1.3-0.1c2.1-0.4,3.9-1.5,5-3.3c0-0.1,0.1-0.2,0-0.3C22.6,20.4,22.6,20.3,22.5,20.3z%20M17.4,23.4%20c-0.4,0.1-0.8,0.1-1.2,0.1c0,0,0,0,0,0c-3.5,0-6.7-2.5-7.5-5.9c-0.5-2.3,0.2-4.7,1.9-6.3l4.9,5.4c0,0,0,0,0.1,0.1l6.3,3.9%20C20.8,22.1,19.3,23.1,17.4,23.4z'/%3e%3cpath%20style='&st5;'%20d='M24.1,14.2c-0.1-0.3-0.2-0.7-0.3-1c0,0,0-0.1,0-0.1c-0.3-0.7-0.7-1.4-1.1-2c0,0,0-0.1-0.1-0.1c0,0,0,0,0,0%20c-0.5-0.5-1-1-1.6-1.4c0,0,0,0,0,0c0,0-0.1-0.1-0.1-0.1c-0.5-0.3-0.9-0.5-1.5-0.7C19.2,8.7,19,8.8,19,9l-2.3,6.4c0,0,0,0,0,0l0,0%20c0,0.1,0,0.3,0.1,0.4l5.9,3.7c0.1,0,0.1,0.1,0.2,0.1c0.1,0,0.2-0.1,0.3-0.2C24.2,17.9,24.5,16,24.1,14.2z%20M20.5,17.3l2.9-3.3%20c0,0.1,0.1,0.2,0.1,0.4c0.1,0.6,0.2,1.1,0.1,1.7l-1.9,2.1L20.5,17.3z%20M18.6,16.1l3.8-4.3c0.3,0.4,0.6,0.9,0.8,1.4l-3.3,3.7%20L18.6,16.1z%20M19.5,9.5c0.3,0.1,0.5,0.2,0.8,0.4l-1.5,1.7L19.5,9.5z%20M18.1,13.3l2.7-3c0.4,0.3,0.8,0.6,1.1,1L18,15.8l-0.6-0.4%20L18.1,13.3z%20M22.8,18.8l-0.5-0.3l1.1-1.2C23.3,17.8,23.1,18.3,22.8,18.8z'/%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
11/13/2026
BreakingRegulationRetina
US FDA Orders GLP-1 Makers to Warn of Potential for Vision Loss
The US FDA announced Nov. 9 that it would require safety labeling changes for the entire class of glucagon-like peptide-1 (GLP-1) receptor agonists, including the popular weight loss drugs Wegovy a...
11/13/2026
BreakingChinaMyopiaRefractiveRegulationSurgical
Chinese Regulators Approve PT Lunana Phakic IOL from Zeiss for Myopia
German company Carl Zeiss Meditec announced on Nov. 9 that China’s National Medical Products Administration (NMPA) had approved the company’s PT Lunana phakic intraocular lens (IOL). The lens was s...
11/13/2026
BreakingCataractDry EyeGlaucomaIOLPharmaRefractiveRetinaRevenueSurgical
Q3-2026 Ophthalmic Revenue Roundup for Alcon, Harrow, STAAR Surgical, ANI, and Sight Sciences
Alcon reported Nov. 10 that its Q3-2026 net sales were $2.7 billion, a 5 percent increase (+5 percent cc) over $2.6 billion in Q3-2025. Surgical net sales for implantables, consumables, and equipme...
11/13/2026
BreakingMyopiaPharmaRegulation
Santen Gains Korean Marketing Approval for Ryjusea (Atropine) for Myopia
Japan’s Santen Pharmaceutical announced Nov. 2 that it had gained marketing approval in South Korea for preservative-free Ryjusea low-dose atropine drops to slow the progression of pediatric myopia...
11/13/2026
BreakingOptometryRegulationScope of Practice
Alberta Is First Province in Canada to Authorize Optometric Surgery
Alberta on Nov. 1 became the first province in Canada to allow qualified optometrists with additional training to perform certain minor surgical and laser procedures in their offices. Under the exp...
11/13/2026
BreakingPresbyopiaTelehealth
Tenpoint Launches Telehealth Prescribing Option for Yuvezzi Presbyopia Drops
Tenpoint Therapeutics announced Nov. 9 that it was making its presbyopia drop, Yuvezzi, available online through a telehealth platform at orderyuvezzi.com. Tenpoint said the site offers patients a ...
11/13/2026
BreakingDealsEmergingRetina
Emerging Company Imvionix Acquires Rights to Beovu in US, Canada
Imvionix, a privately held emerging retinal pharmaceutical company, announced Nov. 10 that it had acquired exclusive commercial rights to Beovu (brolucizumab-dbll) in the US and Canada from Novarti...
11/13/2026
BreakingRegulationRetina
US FDA Grants Orphan Drug Status to Octant’s Oral RP Candidate
Octant, of Emeryville, California, announced Oct. 27 that the US FDA had granted orphan drug status to OCT-980, an oral treatment candidate targeting retinitis pigmentosa (RP). Orphan drug designat...
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cpath%20style='&st2;'%20d='M19.2,10.1c-1.3,0-2.6,0.7-3.4,1.8c-0.8-1.1-2-1.8-3.4-1.8c-2.3,0-4.2,2.1-4.2,4.6c0,0.6,0.1,1.1,0.3,1.7%20c0,0,0,0,0,0c0,0.1,0.1,0.2,0.1,0.3c0.2,0.5,0.5,0.9,0.8,1.3c0.7,0.8,5.9,5.6,6.1,5.8c0.1,0.1,0.2,0.1,0.3,0.1c0.1,0,0.2,0,0.3-0.1%20c0.2-0.2,5.6-5.2,6.4-6.1c0.6-0.8,1-1.9,1-2.9C23.4,12.1,21.5,10.1,19.2,10.1z%20M12.4,10.9c1.2,0,2.4,0.8,3,2%20c0.1,0.1,0.2,0.2,0.4,0.2c0.2,0,0.3-0.1,0.4-0.2c0.6-1.2,1.7-2,3-2c1.9,0,3.4,1.7,3.4,3.8c0,0.4-0.1,0.9-0.2,1.3c0,0,0,0,0,0h-4.7%20c-0.2,0-0.3,0.1-0.4,0.2l-0.8,1.9l-2.5-4.7c-0.1-0.1-0.2-0.2-0.4-0.2c-0.1,0-0.3,0.1-0.4,0.2L11.5,16H9.2C9.1,15.6,9,15.1,9,14.7%20C9,12.6,10.6,10.9,12.4,10.9z%20M15.8,22.9c-1.1-1-5.2-4.8-5.7-5.5c-0.2-0.2-0.3-0.4-0.4-0.6h2.1c0.1,0,0.3-0.1,0.4-0.2l1.4-2.2%20l2.5,4.8c0.1,0.1,0.2,0.2,0.4,0.2c0,0,0,0,0,0c0.2,0,0.3-0.1,0.4-0.2l1.1-2.4H22c-0.1,0.1-0.1,0.2-0.2,0.3%20C21.2,17.8,17.5,21.3,15.8,22.9z'/%3e%3cpath%20style='&st2;'%20d='M16,30.6C8,30.6,1.4,24,1.4,16C1.4,7.9,8,1.4,16,1.4S30.6,7.9,30.6,16C30.6,24,24,30.6,16,30.6z%20M16,2.4%20C8.5,2.4,2.4,8.5,2.4,16S8.5,29.6,16,29.6S29.6,23.5,29.6,16S23.5,2.4,16,2.4z'/%3e%3c/g%3e%3c/svg%3e)
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3cpath%20style='&st5;'%20d='M13.7,10h2.1c0.2,0,0.4-0.2,0.4-0.4S16,9.2,15.8,9.2h-2.1c-0.2,0-0.4,0.2-0.4,0.4S13.4,10,13.7,10z'/%3e%3cpath%20style='&st5;'%20d='M18.3,10.3h-4.7c-0.2,0-0.4,0.2-0.4,0.4s0.2,0.4,0.4,0.4h4.7c0.2,0,0.4-0.2,0.4-0.4S18.6,10.3,18.3,10.3z'%20/%3e%3cpath%20style='&st5;'%20d='M18.3,11.3h-4.7c-0.2,0-0.4,0.2-0.4,0.4c0,0.2,0.2,0.4,0.4,0.4h4.7c0.2,0,0.4-0.2,0.4-0.4%20C18.7,11.5,18.6,11.3,18.3,11.3z'/%3e%3cpath%20style='&st5;'%20d='M21.9,19.2h1.4c0.6,0,1.1-0.5,1.1-1.1v-1.4c0-0.6-0.5-1.1-1.1-1.1h-1.4c-0.6,0-1.1,0.5-1.1,1.1V17h-3.3%20l-1.2-1.2c0,0,0,0,0,0v-2.1H19c1,0,1.8-0.8,1.8-1.8V9.4c0-1-0.8-1.8-1.8-1.8H13c-1,0-1.8,0.8-1.8,1.8V12c0,1,0.8,1.8,1.8,1.8h2.6%20v2.1c0,0,0,0,0,0L14.4,17h-1.9v-0.3c0-0.6-0.5-1.1-1.1-1.1H8.7c-0.6,0-1.1,0.5-1.1,1.1v1.4c0,0.6,0.5,1.1,1.1,1.1h2.8%20c0.6,0,1.1-0.5,1.1-1.1v-0.3h1.9l1.2,1.2v1.9h-0.3c-0.6,0-1.1,0.5-1.1,1.1v1.4c0,0.6,0.5,1.1,1.1,1.1h1.4c0.6,0,1.1-0.5,1.1-1.1%20V23h3.1c0.2,0.8,0.9,1.4,1.7,1.4c1,0,1.8-0.8,1.8-1.8c0-1-0.8-1.8-1.8-1.8c-0.8,0-1.6,0.6-1.7,1.4h-3.1v-0.3%20c0-0.6-0.5-1.1-1.1-1.1h-0.3V19l1.2-1.2h3.3v0.3C20.8,18.7,21.3,19.2,21.9,19.2z%20M23.6,18.1c0,0.2-0.1,0.3-0.3,0.3h-1.4%20c-0.2,0-0.3-0.1-0.3-0.3v-1.4c0-0.2,0.1-0.3,0.3-0.3h1.4c0.2,0,0.3,0.1,0.3,0.3V18.1z%20M16.8,17.4L16,18.2l-0.8-0.8l0.8-0.8%20L16.8,17.4z%20M19,13H13c-0.6,0-1-0.5-1-1V9.4c0-0.6,0.5-1,1-1H19c0.6,0,1,0.4,1,1V12C20,12.5,19.5,13,19,13z%20M15,21.9%20c0-0.2,0.1-0.3,0.3-0.3h1.4c0.2,0,0.3,0.1,0.3,0.3v1.4c0,0.2-0.1,0.3-0.3,0.3h-1.4c-0.2,0-0.3-0.1-0.3-0.3V21.9z%20M8.4,16.7%20c0-0.2,0.1-0.3,0.3-0.3h2.8c0.2,0,0.3,0.1,0.3,0.3v1.4c0,0.2-0.1,0.3-0.3,0.3H8.7c-0.2,0-0.3-0.1-0.3-0.3V16.7z%20M21.6,22.6%20c0-0.6,0.4-1,1-1c0.6,0,1,0.4,1,1c0,0.6-0.4,1-1,1C22.1,23.6,21.6,23.2,21.6,22.6z'/%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Extensive analysis
- Integrated disease models
- Expert-based segmentation
Integrate and reconcile
- Continuous feedback loop
- Integration of survey data
- Triangulation of results
- Cross-model analysis
- Reconciliation to company revenues
Produce products covering key medical markets
- Medical devices
- Drugs/biologics
- Equipment
- Providers
Gather feedback
- New market insights
- Client requests
- Landmark study evaluations
Incorporate and revise
- Forecasting models
- Analytical tools and methods
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.